Kenneth Hoberman
Chief Operating Officer at STEMLINE THERAPEUTICS, INC.
Net worth: 4 M $ as of 2024-04-29
Kenneth Hoberman active positions
Companies | Position | Start | End |
---|---|---|---|
STEMLINE THERAPEUTICS, INC. | Chief Operating Officer | 2012-12-31 | - |
Corporate Secretary | 2012-12-31 | - | |
TG THERAPEUTICS, INC. | Director/Board Member | 2014-12-14 | - |
Independent Dir/Board Member | 2014-12-14 | - | |
NUVECTIS PHARMA, INC. | Director/Board Member | 2021-06-30 | - |
Independent Dir/Board Member | 2021-06-30 | - | |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Director/Board Member | 2021-10-31 | - |
Career history of Kenneth Hoberman
Former positions of Kenneth Hoberman
Companies | Position | Start | End |
---|---|---|---|
KERYX BIOPHARMACEUTICALS | Corporate Officer/Principal | 2003-12-31 | 2011-12-31 |
Training of Kenneth Hoberman
Boston University | Undergraduate Degree |
Statistics
International
United States | 6 |
Israel | 2 |
Operational
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Chief Operating Officer | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
TG THERAPEUTICS, INC. | Health Technology |
NUVECTIS PHARMA, INC. | Health Technology |
Private companies | 3 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Kenneth Hoberman
- Experience